Diaceutics Plc logo

Diaceutics Plc(LSE) DXRX

Market Cap£169.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)+109%
5 Year+78%
1 Year+23%
1 Month+34%
£2.07
+3.76%
+0.07Today
Diaceutics Plc last closing stock price
MetricPriceDate
Last closeGBX 199.002026-10-07
Diaceutics Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.92%GBX 191.502026-09-30
1 month+34.01%GBX 148.502026-09-07
3 month+38.68%GBX 143.502026-07-09
Year to date+55.47%GBX 128.002025-12-31
1 year+22.84%GBX 162.002025-10-07
3 year+102.03%GBX 98.502023-10-06
5 year+78.48%GBX 111.502021-10-08
Since inception+108.9%GBX 0.962019-03-21

Diaceutics Plc Financials at a Glance

Market Cap

£169.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£75.73M

Net Income (TTM)

-£1.79M

EPS (TTM)

-£0.00

P/E Ratio

-623.44

Dividend

£0.00

Beta (Volatility)

-0.02 (Low)

Price

£2.07

Volume

334,059

Open

£1.99

Previous Close

£2.00

Daily Range

£1.99 - £2.07

52-Week Range

£1.25 - £2.07

Estimated Earnings Date

Mar 15, 2027

DXRX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Diaceutics Plc

Diaceutics PLC, established in 2005 and headquartered in Belfast, UK, is focused on accelerating the commercialization of diagnostic solutions. The company provides pharmaceutical firms with comprehensive data, advanced analytics, and implementation support through its innovative DXRX platform.

Products and Services
  • DXRX data solutions for extensive diagnostic testing data access
  • DXRX Patient Journey for longitudinal analyses of patient biomarker testing
  • DXRX Lab Benchmarking for competitive analysis among laboratories
Growth Outlook
  • Revenue increased to £17.46 million in Q2 2026, showing growth potential
  • TTM gross profit margin stands at 67.81%, indicating strong profitability
  • Cash flow from operations reached £3.42 million in Q2 2026, supporting operational stability
Financial Highlights
  • Net income for Q2 2026 was -£2.77 million, reflecting ongoing investment in growth
  • Current ratio of 2.55 suggests strong liquidity position
  • Market capitalization is approximately £159.53 million, indicating solid market presence
Diaceutics PLC operates in the healthcare information services sector, providing essential tools for precision medicine diagnostics. The DXRX platform is central to its offerings, enabling pharmaceutical companies to access critical data and analytics for better patient outcomes. The company has shown resilience in its financial performance, with a notable increase in revenue and a strong gross profit margin. Despite recent net losses, the positive cash flow from operations and a robust current ratio highlight the company's ability to sustain its operations and invest in future growth. With a market capitalization of approximately £159.53 million, Diaceutics PLC is positioned as a significant player in the healthcare analytics space, making it an intriguing option for potential investors interested in the evolving landscape of precision medicine.
AI Generated • Oct 1, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

205

CEO

Ryan Gerard Keeling

Website

diaceutics.com

Headquarters

Belfast, AT BT9 6GW, GB

DXRX Financials

Key Financial Metrics (TTM)

Gross Margin

67.81%

Operating Margin

-2.28%

Net Income Margin

-0.66%

Return on Equity

-0.68%

Return on Capital

0.64%

Return on Assets

-0.52%

Earnings Yield

-0.16%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

£169.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

84.90M

Volume

334.06K

Avg. Volume

256.28K

Financials (TTM)

Gross Profit

£57.65M

Operating Income

-£3.16M

EBITDA

£8.22M

Operating Cash Flow

£4.22M

Capital Expenditure

-£131.00K

Free Cash Flow

£4.09M

Cash & ST Invst.

£8.10M

Total Debt

£2.09M

Diaceutics Plc Performance Analysis

Diaceutics Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31GBP 19,504,00039.9%
20232023-12-31GBP 23,699,00021.5%
20242024-12-31GBP 32,158,00035.7%
20252025-12-31GBP 38,437,00019.5%
Diaceutics Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3161.0%
Q22025-06-30-26.6%
Q42025-12-3163.9%
Q22026-06-30-26.9%
Diaceutics Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31GBP 0.0127.3%
20232023-12-31GBP -0.02N/A
20242024-12-31GBP -0.02-2.4%
20252025-12-31GBP 0.00N/A
Diaceutics Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31134.0%
Q22025-06-30-373.1%
Q42025-12-31203.9%
Q22026-06-30-210.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

£17.46M

+41.7%

Gross Profit

£11.74M

+36.3%

Gross Margin

67.27%

N/A

Market Cap

£169.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£826.24K

N/A

Employees

205

N/A

Net Income

-£2.77M

-7.2%

EBITDA

-£722.00K

+24.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

£8.10M

-51.6%

Total Debt

£2.09M

+84.7%

Accounts Receivable

£18.69M

+93.0%

Inventory

£0.00

N/A

Long Term Debt

£1.82M

+84.8%

Short Term Debt

£276.00K

+84.0%

Return on Assets

-0.52%

N/A

Return on Invested Capital

-2.32%

N/A

Free Cash Flow

£3.40M

+136.3%

Operating Cash Flow

£3.42M

+128.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TSTL.LTristel PLC
£4.28+0.61%
BXP.LBeximco Pharmaceuticals Limited
£0.51-4.78%
ANCR.LAnimalcare Group plc
£3.35+0.45%
EKF.LEKF Diagnostics Holdings plc
£0.24+1.04%

Trending Stocks

Symbol / CompanyPricePrice Chg
BULLWebull
$5.86-19.49%
INTCIntel
$113.57+0.95%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$31.22+5.37%
NOKNokia
$10.65-2.92%

Questions About DXRX

What is the current price of Diaceutics Plc?

Diaceutics Plc is trading at £2.07 per share.

What is the 52-week range for Diaceutics Plc?

Over the past 52 weeks, Diaceutics Plc has traded between £1.25 and £2.07.

How much debt does Diaceutics Plc have?

As of the most recent reporting period, Diaceutics Plc reported total debt of £1.15M.

How much cash does Diaceutics Plc have on hand?

Diaceutics Plc reported £7.34M in cash and cash equivalents in its most recent financial results.

What is Diaceutics Plc’s dividend yield?

Diaceutics Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services